🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

30 recruiting trials

for Leukemia, Myeloid, Chronic

Chemotherapy (Decitabine in Combination With FLAG-Ida) and Total-Body Irradiation Followed by Donor Stem Cell Transplant for the Treatment of Adults With Myeloid Malignancies at High Risk of Relapse NCT06928662Phase 1, Phase 21 site📍 Seattle Fred Hutchinson Cancer Center · Tests: Decitabine, Bone Marrow Aspiration, Bone Marrow Biopsy, Chest Radiography, Cytarabine A Phase 2 Study Evaluating Olutasidenib in Patients With IDH1-mutated Clonal Cytopenia of Undetermined Significance and Lower-risk Myelodysplastic/Syndromes/Chronic Myelomonocytic Leukemia. NCT06566742Phase 22 sites📍 Miami📍 Houston M.D. Anderson Cancer Center · Tests: Olutasidenib Intestinal Microbiota Transplant Prior to Allogeneic Stem Cell Transplant (MAST) Trial NCT06355583Phase 28 sites📍 Birmingham📍 Leeds📍 London Imperial College London · Tests: EBX-102, Placebo Venetoclax in Addition to Sequential Conditioning With Fludarabine / Amsacrine / Ara-C (FLAMSA) + Treosulfan for Allogeneic Blood Stem Cell Transplantation in Patients With MDS, CMML or sAML NCT05807932Phase 1, Phase 26 sites📍 Aachen📍 Düsseldorf📍 Cologne Heinrich-Heine University, Duesseldorf · Tests: Venetoclax, Amsacrine, Ara-C, Tacrolimus, Mycophenolate Mofetil Olutasidenib for the Treatment of Patients With IDH1 Mutated AML, MDS or CMML After Donor Hematopoietic Cell Transplant NCT06543381Phase 12 sites📍 Duarte📍 Cleveland City of Hope Medical Center · Tests: Biospecimen Collection, Olutasidenib IMM01+Azacitidine VS Placebo +Azacitidine in Patients With Newly Diagnosed Chronic Myelomonocytic Leukemia (CMML1-2) NCT06647862Phase 343 sites📍 Hefei📍 Beijing📍 Chongqing ImmuneOnco Biopharmaceuticals (Shanghai) Inc. · Tests: IMM01, Azacitidine, Placebo Q702 for the Treatment of Patients With Hematologic Malignancies NCT06712810Phase 12 sites📍 Scottsdale📍 Rochester Mayo Clinic · Tests: Axl/Mer/CSF1R Inhibitor Q702, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography CPX-351 in Treating Patients With Relapsed or Refractory High Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia NCT03896269Phase 11 site📍 Houston M.D. Anderson Cancer Center · Tests: Liposome-encapsulated Daunorubicin-Cytarabine Blinatumomab, Methotrexate, Cytarabine, and Ponatinib in Treating Patients With Philadelphia Chromosome-Positive, or BCR-ABL Positive, or Relapsed/Refractory, Acute Lymphoblastic Leukemia NCT03263572Phase 21 site📍 Houston M.D. Anderson Cancer Center · Tests: Blinatumomab, Cytarabine, Methotrexate, Ponatinib Allo HSCT Using RIC and PTCy for Hematological Diseases NCT05805605Phase 21 site📍 Minneapolis Masonic Cancer Center, University of Minnesota · Tests: Peripheral Blood Stem Cell Transplant, Allopurinol 300 MG, Fludarabine, Cyclophosphamide, Bone Marrow Cell Transplant The Prospective Collection, Storage and Reporting of Data on Patients Undergoing Hematopoietic Stem Cell Transplantation Utilizing a Standard Preparative Regimen NCT01890486n/a1 site📍 Winston-Salem Wake Forest University Health Sciences Autologous T Cells Transduced With Retroviral Vectors Expressing TCRs for Participant-specific Neoantigens in Patients With Hematologic Malignancies NCT06904066Phase 11 site📍 Bethesda National Cancer Institute (NCI) · Tests: aldesleukin, cyclophosphamide, fludarabine phosphate, Individual Patient TCR-Transduced PBL, TruSight Oncology (TSO) 500 Olverembatinib Combined With Venetoclax and Azacitidine in Blast Phase Ph Chromosome-positive CML NCT06757855Phase 1, Phase 21 site📍 Tianjin Institute of Hematology & Blood Diseases Hospital, China · Tests: Olverembatinib, Venetoclax, Azacitidine Venetoclax to Improve Outcomes of Fractionated Busulfan Regimen in Patients With High-Risk AML and MDS NCT04708054Phase 2, Phase 31 site📍 Houston M.D. Anderson Cancer Center · Tests: Busulfan, Cladribine, Fludarabine Phosphate, Hematopoietic Cell Transplantation, Thiotepa Unrelated Umbilical Cord Blood Stem Cell Combined With Azacitidine Based Treatment for Advanced MDS,CMML-2 and sAML NCT05584761Phase 1, Phase 21 site📍 Nanjing The First Affiliated Hospital with Nanjing Medical Universi… · Tests: unrelated umbilical cord blood Myeloproliferative Neoplasms (MPNs) Patient Registry NCT02760238n/a1 site📍 Toronto University Health Network, Toronto · Tests: Observational A Study on the Tolerability, Safety and Effectiveness of Asciminib in Patients With Philadelphia Chromosome-positive Chronic Myeloid Leukemia in the Chronic Phase in Germany NCT07549516n/a69 sites📍 Baden-Baden📍 Heidenheim📍 Schwäbisch Hall Novartis Pharmaceuticals Total Marrow and Lymphoid Irradiation in Combination With Fludarabine and Melphalan as Conditioning for Allogeneic Peripheral Blood Stem Cell Hematopoietic Cell Transplant in Older Patients With Refractory and Relapsed Acute Myeloid Leukemia and High-risk Myelodysplastic Syndrome NCT07582172Phase 21 site📍 Duarte City of Hope Medical Center · Tests: Biospecimen Collection, Bone Marrow Biopsy, Computed Tomography, Echocardiography Test, Fludarabine Phosphate A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs) NCT01351545n/a142 sites📍 Birmingham📍 Gilbert📍 Phoenix Center for International Blood and Marrow Transplant Resear… · Tests: A multicenter access and distribution protocol for unlicensed cryopreserved cord blood units (CBUs) Safety and Efficacy of Ponatinib for Treatment of Pediatric Recurrent or Refractory Leukemias, Lymphomas or Solid Tumors NCT03934372Phase 1, Phase 223 sites📍 Ghent📍 Paris📍 Paris Incyte Biosciences International Sàrl · Tests: Ponatinib HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant NCT03326921Phase 11 site📍 Seattle Fred Hutchinson Cancer Center · Tests: CD8+ and CD4+ Donor Memory T-cells-expressing HA1-Specific TCR, Bone Marrow Aspiration, Biospecimen Collection TACrolimus Targeted Immunosuppression Cessation in ALlogeneic HCT NCT07302776Phase 11 site📍 Palo Alto Stanford University · Tests: Tacrolimus, Early Tacrolimus Taper Strategy Edetate Calcium Disodium or Succimer in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Undergoing Chemotherapy NCT03630991Phase 11 site📍 Houston M.D. Anderson Cancer Center · Tests: Edetate Calcium Disodium, Multivitamin, Succimer A Real-world Chronic Myelogenous Leukemia (CML) Patient Disease Registry to Describe Patient Experience and Clinical Outcomes Among Patients With CML Receiving Approved First or Second Line Tyrosine Kinase Inhibitor (TKI) Therapy NCT07091019n/a17 sites📍 Birmingham📍 Stockton📍 Torrance Novartis Pharmaceuticals · Tests: TKIs Evaluation of Advanced Practice Nurse's Management of Patients With Chronic Myeloid Leukemia NCT06082804NA1 site📍 Avignon Centre Hospitalier Henri Duffaut - Avignon · Tests: APN and medical management, Medical management, Quality of life assessment, Treatment compliance assessment Screening Study for KIT D816V Mutated Mast Cell Disease in Select Populations NCT07143669n/a26 sites📍 Birmingham📍 Birmingham📍 Scottsdale Blueprint Medicines Corporation · Tests: Screening A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation NCT06859424Phase 213 sites📍 Birmingham📍 Duarte📍 Palo Alto Center for International Blood and Marrow Transplant Resear… · Tests: Conditioning Regimen A, Conditioning Regimen B, Conditioning Regimen C, Conditioning Regimen D, Conditioning Regimen E Study of Olverembatinib (HQP1351) in Patients With CML-CP NCT06423911Phase 3163 sites📍 Birmingham📍 Anchorage📍 Goodyear Ascentage Pharma Group Inc. · Tests: olverembatinib, Bosutinib Cladribine, Idarubicin, Cytarabine, and Venetoclax in Treating Patients With Acute Myeloid Leukemia, High-Risk Myelodysplastic Syndrome, or Blastic Phase Chronic Myeloid Leukemia NCT02115295Phase 21 site📍 Houston M.D. Anderson Cancer Center · Tests: Cladribine, Cytarabine, Gilteritinib, Idarubicin, Laboratory Biomarker Analysis Optimization of Post-transplantation Benadamustine and Cyclophosphamide in Patients With High-risk Myeloid Malignancies and a Partially Mismatched Donor NCT07238712Phase 21 site📍 Saint Petersburg St. Petersburg State Pavlov Medical University · Tests: Ruxolitinib, Abatacept (Orencia)
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy